enVVeno Medical (NASDAQ:NVNO) and Orchestra BioMed (NASDAQ:OBIO) Financial Review

Orchestra BioMed (NASDAQ:OBIO) and enVVeno Medical (NASDAQ:NVNO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Risk & Volatility

Orchestra BioMed has a beta of 0.42, suggesting that its stock price is 58% less volatile than the S&P 500. Comparatively, enVVeno Medical has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500.

Valuation & Earnings

This table compares Orchestra BioMed and enVVeno Medical”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orchestra BioMed	$2.76 million	79.60	-$49.12 million	($1.61)	-3.59
enVVeno Medical	N/A	N/A	-$23.52 million	($1.29)	-2.47

enVVeno Medical has lower revenue, but higher earnings than Orchestra BioMed. Orchestra BioMed is trading at a lower price-to-earnings ratio than enVVeno Medical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Orchestra BioMed and enVVeno Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Orchestra BioMed	-2,179.33%	-107.04%	-70.88%
enVVeno Medical	N/A	-48.72%	-45.96%

Institutional & Insider Ownership

53.6% of Orchestra BioMed shares are held by institutional investors. Comparatively, 34.7% of enVVeno Medical shares are held by institutional investors. 6.7% of Orchestra BioMed shares are held by company insiders. Comparatively, 17.0% of enVVeno Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Orchestra BioMed and enVVeno Medical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orchestra BioMed	0	0	4	0	3.00
enVVeno Medical	0	0	0	0	0.00

Orchestra BioMed currently has a consensus price target of $15.75, indicating a potential upside of 172.49%. Given Orchestra BioMed’s stronger consensus rating and higher probable upside, analysts plainly believe Orchestra BioMed is more favorable than enVVeno Medical.

Summary

enVVeno Medical beats Orchestra BioMed on 8 of the 13 factors compared between the two stocks.

About Orchestra BioMed

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company’s flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

About enVVeno Medical

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®?, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial.